Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial

Diabetes is an independent risk factor for cognitive impairment. We aimed to investigate the association between the glucagon-like peptide-1 (GLP-1) receptor agonist dulaglutide and cognitive impairment as an exploratory analysis within the Researching Cardiovascular Events With a Weekly Incretin in...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Lancet neurology 2020-07, Vol.19 (7), p.582-590
Hauptverfasser:	Cukierman-Yaffe, Tali, Gerstein, Hertzel C, Colhoun, Helen M, Diaz, Rafael, García-Pérez, Luis-Emilio, Lakshmanan, Mark, Bethel, Angelyn, Xavier, Denis, Probstfield, Jeffrey, Riddle, Matthew C, Rydén, Lars, Atisso, Charles Messan, Hall, Stephanie, Rao-Melacini, Purnima, Basile, Jan, Cushman, William C, Franek, Edward, Keltai, Matyas, Lanas, Fernando, Leiter, Lawrence A, Lopez-Jaramillo, Patricio, Pirags, Valdis, Pogosova, Nana, Raubenheimer, Peter J, Shaw, Jonathan E, Sheu, Wayne H-H, Temelkova-Kurktschiev, Theodora
Format:	Artikel
Sprache:	eng
Schlagworte:	Antidiabetics Cardiovascular diseases Cerebral infarction Cognitive ability Dementia Diabetes Diabetes mellitus (non-insulin dependent) GLP-1 receptor agonists Glucagon Glucagon-like peptide 1 Heart attacks Hemoglobin Insulin Memory Myocardial infarction Peptides Risk factors Validation studies
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!